Impact of dose reductions on efficacy outcome in heart transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil at 12 months post-transplantation

Clinical Transplantation

Volumn 22, Issue 6, 2008, Pages 809-814

  Segovia, Javier ^a   Gerosa, G ^s   Almenar, Luis ^c   Livi, Ugolino ^d,w   Viganò, Mario ^e,ad   Arizón, Jose Maria ^f   Yonan, Nizar ^g,ae   Di Salvo, Thomas G ^h,o   Renlund, Dale G ⁱ   Kobashigawa, J ^j   Aaronson, K ^k   Ahualli, L ^l   Arpesella, G ^m   Crespo, M G ⁿ   Davis, S F ^o   Butler, J ^o   Dengler, T ^p   Egan, J ^q   Eisen, H J ^r   Haddad, H ^t   Davies, R ^t   Keogh, A M ^u   Lehmkuhl, H B ^v   Hummel, M ^v   Hetzer, R ^v   Miller, L W ^x   Modry, D ^y   Burton, J ^y   Mullen, G M ^z   Pisani, B ^z   Murday, A J ^aa   Ross, H ^ab   Alonso Pulpon, L ^a   Perrone, S ^ac   Zucker, M J ^af   more..

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

^d UNIVERSITY HOSPITAL OF UDINE   (Italy)

^e University and Research Hospital   (Italy)

^f HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^g WYTHENSHAWE HOSPITAL   (United Kingdom)

^h VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF UTAH   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^l HOSPITAL GENERAL DE AGUDOS DR COSME ARGERICH   (Argentina)

^m UNIVERSITY OF BOLOGNA   (Italy)

ⁿ HOSPITAL JUAN CANALEJO   (Spain)

^o Vanderbilt University Transplant Center   (United States)

^p UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^q MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^r TEMPLE UNIVERSITY   (United States)

^s UNIVERSITY OF PADOVA   (Italy)

^t UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^u ST VINCENT S HOSPITAL   (Australia)

^v DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^w Azienda Osp Udine   (Italy)

^x UNIVERSITY OF MINNESOTA   (United States)

^y UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^z LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^aa Scottish Cardiopulmonary Transplant Unit   (United Kingdom)

^ab TORONTO GENERAL HOSPITAL   (Canada)

^ac HOSPITAL UNIVERSITARIO FUNDACIÓN FAVALORO   (Argentina)

^ad FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^ae Cardiothoraxic Transplant Centre   (United Kingdom)

^af NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

more..

Author keywords

Acute rejection; Clinical outcome; Dose reduction; Enteric coated mycophenolate sodium; Heart transplantation; Mycophenolate mofetil

Indexed keywords

BASILIXIMAB; CYCLOSPORIN A; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CARDIAC GRAFT REJECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TREATMENT FAILURE; ENTERIC COATED TABLET; FATALITY; FEMALE; HEART DISEASE; HEART GRAFT; HEART MUSCLE BIOPSY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RISK ASSESSMENT; SINGLE BLIND PROCEDURE;

EID: 56349103655     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2008.00887.x     Document Type: Article

References (21)

1. Kobashigawa J, Miller L, Renlund D et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation 1998: 66: 507.
2. Kobashigawa JA, Meiser BM. Review of major clinical trials with mycophenolate mofetil in cardiac transplantation. Transplantation 2005: 80: S235.
3. Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management. Drug Saf 2001: 24: 645.
4. Shipkova M, Armstrong VW, Oellerich M, Wieland E. Mycophenolate mofetil in organ transplantation: Focus on metabolism, safety and tolerability. Expert Opin Drug Metab Toxicol 2005: 1: 505.
5. Díaz B, González Vilchez F et al.; MITOS Study Group. Gastrointestinal complications in heart transplant patients: MITOS Study. Transplant Proc 2007: 39: 2397.
6. Pelletier RP, Akin B, Henry ML et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 2003: 17: 200.
7. Knoll GA, Mac Donald I, Khan A, Van Walraven C. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003: 14: 2381.
8. Hardinger KL, Brennan DC, Lowell J, Schnitzler MA. Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. Transpl Int 2004: 17: 609.
9. Tierce JC, Porterfield-Baxa J, Petrilla AA, Kilburg A, Ferguson RM. Impact of mycophenolate mofetil (MMF)-related gastrointestinal complications and MMF dose alterations on transplant outcomes and healthcare costs in renal transplant recipients. Clin Transplant 2005: 19: 779.
10. Kahu J, Kyllönen L, Salmela K. Impact of mycophenolate mofetil intolerance on early results of kidney transplantation. Transplant Proc 2005: 37: 3276.
11. Bunnapradist S, Lentine KL, Burroughs TE et al. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure. Transplantation 2006: 82: 102.
12. Arns W, Breuer S, Choudhury S et al. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin Transplant 2005: 19: 199.
13. Johnston A, He X, Holt DW. Bioequivalence of enteric-coated mycophenolate sodium and mycophenolate mofetil: A meta-analysis of three studies in stable renal transplant recipients. Transplantation 2006: 82: 1413.
14. Budde K, Curtis J, Knoll G et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant 2004: 4: 237.
15. Salvadori M, Holzer H, de Mattos A et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004: 4: 231.
16. Chan L, Mulgaonkar S, Walker R, Arns W, Ambühl P, Schiavelli R. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplantation 2006: 81: 1290.
17. Tomlanovich S, Bolin P, Tanriover B et al. A 3-month, prospective, open-label, two-cohort study to investigate the efficacy, safety, and tolerability of EC-MPS in combination with cyclosporine or tacrolimus in renal transplant recipients with gastrointestinal intolerance. Transplantation 2006: 82: 1245.
18. Kobashigawa JA, Renlund DG, Gerosa G et al.; ERL2401 Heart Study Investigators. Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: Results of a 12-month, single-blind, randomized, parallel-group, multicenter study. J Heart Lung Transplant 2006: 25: 935.
19. Hummel M, Yonan N, Ross H et al.; ERL 2401 Study Group. Pharmacokinetics and variability of mycophenolic acid from enteric-coated mycophenolate sodium compared with mycophenolate mofetil in de novo heart transplant recipients. Clin Transplant 2007: 21: 18.
20. Boswell A, Rigg K, Shehata M. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in patients with gastrointestinal side effects: Case studies. Prog Transplant 2006: 16: 138.
21. Galiwango PJ, Delgado DH, Yan R et al. Mycophenolate mofetil dose reduction for gastrointestinal intolerance is associated with increased rates of rejection in heart transplant patients. J Heart Lung Transplant 2008: 27: 72.